.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Analyze global market entry opportunities
  • Find suppliers and generic API sources

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Chubb
Daiichi Sankyo
Fish and Richardson
Federal Trade Commission
US Department of Justice
Accenture
Baxter
Chinese Patent Office
Novartis

Generated: June 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,656,650

« Back to Dashboard

Claims for Patent: 5,656,650

Title: Angiotensin II receptor blocking compositions
Abstract:This invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier, an angiotensin II receptor antagonist and a second agent selected from a diuretic, a calcium channel blocker, a .beta.-adrenoceptor blocker, a renin inhibitor, or an angiotensin converting enzyme inhibitor and a method of treating hypertension.
Inventor(s): Weinstock; Joseph (Phoenixville, PA)
Assignee: SmithKline Beecham Corp. (
Application Number:08/444,121
Patent Claims: 1. A pharmaceutical composition comprising a diuretic, a pharmaceutically acceptable carrier and an angiotensin II receptor antagonist of the formula (I): ##STR10## in which: R.sup.1 is adamantyl, phenyl, biphenyl, or naphthyl, with each aryl group being unsubstituted or substituted by one to three substituents selected from Cl, Br, F, I, C.sub.1 -C.sub.6 alkyl, nitro, A--CO.sub.2 R.sup.7, tetrazol-5-yl, C.sub.1 -C.sub.6 alkoxy, hydroxy, SC.sub.1 -C.sub.6 alkyl, SO.sub.2 NHR.sup.7, NHSO.sub.2 R.sup.7, SO.sub.3 H, CONR.sup.7 R.sup.7, CN, SO.sub.2 C.sub.1 -C.sub.6 alkyl, PO(OR.sup.7).sub.2, NR.sup.7 R.sup.7, NR.sup.7 COH, NR.sup.7 COC.sub.1 -C.sub.6 alkyl, NR.sup.7 CON(R.sup.7).sub.2, NR.sup.7 COW, W, or SO.sub.2 W;

m is 0-4;

R.sup.2 is C.sub.2 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, or (CH.sub.2).sub.0-8 phenyl unsubstituted or substituted by one to three substituents selected from C.sub.1 -C.sub.6 alkyl, nitro, Cl, Br, F, I, hydroxy, C.sub.1 -C.sub.6 alkoxy, NR.sup.7 R.sup.7, CO.sub.2 R.sup.7, CN, CONR.sup.7 R.sup.7, W, tetrazol-5-yl, NR.sup.7 COC.sub.1 -C.sub.6 alkyl, NR.sup.7 COW, SC.sub.1 -C.sub.6 alkyl, SO.sub.2 W, or SO.sub.2 C.sub.1 -C.sub.6 alkyl;

X is a single bond, S, NR.sup.7, or O;

R.sup.3 is hydrogen, Cl, Br, F, I, CHO, hydroxymethyl, COOR.sup.7, CONR.sup.7 R.sup.7, NO.sub.2, W, CN, NR.sup.7 R.sup.7, or phenyl;

R.sup.4 and R.sup.5 are independently hydrogen, C.sub.1 -C.sub.6 alkyl, thienyl-Y-, furyl-Y-, pyrazolyl-Y-, imidazolyl-Y-, pyrrolyl-Y-, triazolyl-Y-, oxazolyl-Y-, isoxazolyl-Y-, thiazolyl-Y-, pyridyl-Y-, or tetrazolyl-Y-, except that R.sup.4 and R.sup.5 are not both selected from hydrogen and C.sub.1 -C.sub.6 alkyl and each heterocyclic ring is unsubstituted or substituted by C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, Cl, Br, F, I, NR.sup.7 R.sup.7, CO.sub.2 R.sup.7, SO.sub.2 NHR.sup.7, SO.sub.3 H, or CONR.sup.7 R.sup.7, OH, NO.sub.2, W, SO.sub.2 W, SC.sub.1 -C.sub.6 alkyl, SO.sub.2 C.sub.1 -C.sub.6 alkyl, NR.sup.7 COH, NR.sup.7 COW, or NR.sup.7 COC.sub.1 -C.sub.6 alkyl;

Y is a single bond, O, S, or C.sub.1 -C.sub.6 alkyl which is straight or branched or optionally substituted by phenyl or benzyl, wherein each of the aryl groups is unsubstituted or substituted by halo, NO.sub.2, CF.sub.3, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, CN, or CO.sub.2 R.sup.7 ;

R.sup.6 is --Z--COOR.sup.8 or --Z--CONR.sup.7 R.sup.7 ;

Z is a single bond, vinyl, --CH.sub.2 --O--CH.sub.2 --, methylene optionally substituted by C.sub.1 -C.sub.6 alkyl, one or two benzyl groups, thienylmethyl, or furylmethyl, or --C(O)NHCHR.sup.9 --, wherein R.sup.9 is H, C.sub.1 -C.sub.6 alkyl, phenyl, benzyl, thienylmethyl, or furylmethyl;

W is C.sub.n F.sub.2n+1, wherein n is 1-3;

A is --(CH.sub.2).sub.m --, --CH.dbd.CH--, --O(CH.sub.2).sub.n --, or --S(CH.sub.2).sub.n --;

each R.sup.7 independently is hydrogen C.sub.1 -C.sub.6 alkyl or (CH.sub.2).sub.m phenyl, wherein m is 0-4; and

R.sup.8 is hydrogen, C.sub.1 -C.sub.6 alkyl, or 2-di(C.sub.1 -C.sub.6 alkyl)amino-2-oxoethyl;

or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical composition of claim 1 wherein the angiotensin II receptor antagonist is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thieny l)methyl-2-propenoic acid or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition of claim 2 wherein the angiotensin II receptor antagonist is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thieny l)methyl-2-propenoic acid methanesulfonate.

4. The pharmaceutical composition of claim 3 wherein the diuretic is hydrochlorothiazide or furosemide.

5. The pharmaceutical composition of claim 1 wherein the angiotensin II receptor antagonist is (E)-3-[2-n-butyl-1-{(4-carboxynapthy-1-yl)methyl}-1H-imidazol-5-yl]-2-(2-t hienyl)methyl-2-propenoic acid or a pharmaceutically acceptable salt thereof.

6. The pharmaceutical composition of claim 5 wherein the diuretic is hydrochlorothiazide or furosemide.

7. A pharmaceutical composition comprising a calcium channel blocker, a pharmaceutically acceptable carrier and an angiotensin II receptor antagonist of the formula (I), as described in claim 1.

8. A pharmaceutical composition comprising a .beta.-adrenoceptor blocker, a pharmaceutically acceptable carrier and an angiotensin II receptor antagonist of the formula (I), as described in claim 1.

9. A pharmaceutical composition comprising a renin inhibitor, a pharmaceutically acceptable carrier and an angiotensin II receptor antagonist of the formula (I), as described in claim 1.

10. A pharmaceutical composition comprising an angiotensin converting enzyme inhibitor, a pharmaceutically acceptable carrier and an angiotensin II receptor antagonist of the formula (I), as described in claim 1.

11. A method of treating hypertension which comprises administering stepwise or in physical combination a diuretic and an angiotensin II receptor antagonist of the formula (I), as described in claim 1.

12. The method of claim 11 wherein the angiotensin II receptor antagonist is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thi enyl)methyl-2-propenoic acid or a pharmaceutically acceptable salt thereof.

13. The method of claim 12 wherein the angiotensin II receptor antagonist is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thi enyl)-methyl-2-propenoic acid methanesulfonate.

14. The method of claim 13 wherein the diuretic is hydrochlorothiazide or furosemide.

15. The method of claim 11 wherein the angiotensin II receptor antagonist is (E)-3-[2-n-butyl-1-{(4-carboxynaphth-1-yl)methyl}-1H-imidazol-5-yl]-2-( 2-thienyl)methyl-2-propenoic acid or a pharmaceutically acceptable salt thereof.

16. The method of claim 15 wherein the diuretic is hydrochlorothiazide or furosemide.

17. A method of treating hypertension which comprises administering stepwise or in physical combination a calcium channel blocker and an angiotensin II receptor antagonist of formula (I), as described in claim 1.

18. A method of treating hypertension which comprises administering stepwise or in physical combination a .beta.-adrenoceptor blocker and an angiotensin II receptor antagonist of formula (I), as described in claim 1.

19. A method of treating hypertension which comprises administering stepwise or in physical combination a renin inhibitor and an angiotensin II receptor antagonist of formula (I), as described in claim 1.

20. A method of treating hypertension which comprises administering stepwise or in physical combination an angiotensin converting enzyme inhibitor and an angiotensin II receptor antagonist of formula (I), as described in claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Novartis
Mallinckrodt
Covington
US Department of Justice
Baxter
Boehringer Ingelheim
QuintilesIMS
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot